Trilogy Writing and Consulting Logo

Type: Publications

Communicating with patients - COVER
Communicating With Patients: Why It Matters and How to Do It Better
Welcome to the Medical Writing Supplement of International Clinical Trials. We are delighted to present this edition, where we explore the landscape of communication with patients and the general public....
Journal: Medical Writing Supplement of International Clinical Trials, ICT
Date: February 2024
Screenshot 2023-10-09 112949
AI for Medical Writers – Friend or Foe?
Artificial Intelligence (AI) is beginning to affect almost every industry, and medical writing is no different. But how does this relate to our industry? How will AI affect medical writers? What’s already available and what is in the pipeline? Should medical writers be happy and embrace the technology, or should we resist as much as we can, assuming that we will all be replaced by machines? This article discusses the current state of the art of AI in medical writing and asks the question: AI for medical writers – friend or foe?
Author: Lisa Chamberlain James and Jamie Norman
Journal: Journal for Clinical Studies
Date: September 2023
Clinical study protocol_Julia Forjanic Klapproth_Trilogy Writing
How well-written clinical study protocols get drugs to patients faster
In the world of drug development and approval, time is of the essence. But beginning the process with a poorly written protocol will only impede teams before a study has even begun. Julia Forjanic Klapproth, co-founder of Trilogy Writing & Consulting, describes how a well-written protocol will help patients receive their treatments sooner rather than later.
Author: Julia Forjanic Klapproth
Journal: Clinical Trials Insight
Date: July 2023
Clinical Study Protocols
Clinical Study Protocols: The Pillars of Clinical Development
Welcome to the 2023 Medical Writing Supplement developed as a collaboration between Samedant Ltd and Trilogy Writing & Consulting and published as part of the Winter edition of International Clinical...
Journal: Medical Writing Supplement of International Clinical Trials, ICT
Date: February 2023
AMWA Journal Winter Cover 2022
The Future of Medical Writing: A Panel of One
Of all the points in the evolution of the medical writing profession, I believe we are at the pinnacle of what promises to be the most exciting and biggest paradigm...
Author: Lisa Chamberlain James
Journal: AMWA Journal
Date: December 2022
Medical Writing 31-3
Remote meetings made easy: Good practices to keep in mind
Abstract One core medical writing skill is effectively communicating with the teams that will help us author our documents. With remote working playing an increasingly important role in our workforce,...
Author: Tiago Silva, Catarina Silva, Tiago Campos, Maria Mascarenhas
Journal: Medical Writing Volume 31, Issue 3
Date: 2022
ICT Front Cover
Strategic Benefits
Julia Forjanic Klapproth of Trilogy Writing and Consulting elucidates how strategic medical writingcan help communicate key messages across development programmes and make sure teamsstay focused on a common goal. I...
Author: Julia Forjanic Klapproth
Journal: ICT Medical Writing
Date: Nov 2011
ICT-May-2022
How to Streamline Regulatory Authority Meetings
Streamlining meetings with regulatory authorities is a continually evolving process. But what role do briefing documents play, and what is the best way to produce these effectively?
Author: Maria Mascarenhas and Barry Drees
Journal: International Clinical Trials
Date: May 2022
Cover-Picture-OCT-handbook-2021
Artificial intelligence for medical writing, part two: transparency, flexibility and control
In an earlier article about artificial intelligence (AI) for medical writing1, I stressed that AI tools would assist, accelerate and augment the process of clinical documentation. I also argued that the key to the third aspect, augmentation, was the use and future acceptance of standard texts.
Author: Barry Drees
Journal: Outsourcing in Clinical Trials Handbook 2022
Date: December 2021
OCT-2022-Cover-Page
How to streamline a complex process: why experienced medical writers will add value to oncology dossiers
Oncology is one of the most common areas of drug development in the pharmaceutical industry. In 2020, many of the new drugs approved by the FDA were cancer treatments. Existing...
Author: Julia Forjanic Klapproth and Maurice Löwens
Journal: Clinical Operations in Oncology Trials Handbook 2022
Date: December 2021
ICT-Cover-Page-November-Edition
The FDA, EMA, and PMDA Questions: How to Respond During Review of CTD Submission Dossiers
While the ICH’s Common Technical Document (CTD) is an internationally agreed format for preparing application dossiers needed for obtaining approval to market a drug, the ensuing review process is specific to the country or region in question. Irrespective of the differences in process between countries and regions, questions will almost always be issued during the review process, with a request for written responses.
Author: Douglas Fiebig
Journal: International Clinical Trials
Date: November 2021
Journal-for-Clinical-Studies-Volumne-13-edition-5
Plain Language Summaries of Publications – what has COVID-19 taught us?
The COVID-19 pandemic has significantly impacted the whole world and the public has had to struggle with understanding scientific data on a daily basis. The impact of scientific misunderstanding became painfully apparent with the decline in vaccine uptake and so the need for clear, understandable scientific information has never been more vital.
Author: Lisa Chamberlain James and Rachel Beeby
Journal: Journal for Clinical Studies
Date: October 2021
H1-Journal-Front-Page
Reaping the Benefits from Improved Clinical Study Protocols
Clinical study protocols are important cornerstones on the journey of collecting the clinical data needed to elucidate the benefit-risk profile of medical treatments/devices. Not only do they lay down the plan for the study at hand, they serve as a repository of knowledge for the strategic intentions and will be used for multiple down-stream activities. They are the basis for trial registration, provide guidance to those running the study, and will be used by participants, ethics committees/institutional review boards, funders, regulators, journal editors, and systematic reviewers to appraise the study.
Author: Julia Forjanic Klapproth
Journal: H1 Virtual Events: Review and Summary Handbook
Date: June 2021
Clinical-Trials-Insight-July-2021
Lean Medical Writing: Story not Storage
The most difficult task an author can face is clearly summarising a complex and data-filled clinical regulatory document and explaining the data. Barry Drees, co-founder and senior partner of Trilogy Writing & Consulting, discusses the recent concept of ‘lean medical writing’ (LMW), and how it is being implemented and used in the pharmaceutical industry.
Author: Barry Drees
Journal: Clinical Trials Insight
Date: June 2021
JCS-Summer-2021
Communicating with Patients. Who and How?
Despite the fact that patient-friendly versions of many regulatory documents are now mandated by the regulations, the most frequently encountered reaction to communicating patient information is apathy.
Author: Lisa Chamberlain James
Journal: Journal for Clinical Studies
Date: June 2021
EPC Journal
The Clinical Development Plan – The Importance of Getting it Right
Given the extreme complexity and difficulty of developing new pharmaceutical products, one would think that the planning for such an endeavour would be taken very seriously. Yet, somewhat surprisingly, it frequently is not.
Author: Barry Drees and Julia Forjanic Klapproth
Journal: European Pharmaceutical Contractor, EPC
Date: November 2020
OCT-Handbook-2021
AI for Medical Writing: Assistance, Acceleration and Augmentation
The promise of AI for the field of medical writing has been apparent for some time and a number of teams have created tools of varying effectiveness and scope. Dr....
Author: Barry Drees
Journal: Outsourcing in Clinical Trials Handbook 2021
Date: October 2020
Regulatory-Rapporteur-Article-67-Cover
Do We Need to Involve Patients in Clinical Study Report Lay Summaries?
Translating complex clinical regulatory documents into versions that are understandable to patients and the general public was never going to be an easy task, but it is a very necessary, important, and now legally mandated one. This article argues that the advent of the clinical trial results lay summary requirement has highlighted the need for patient involvement in clinical trials at the very earliest stages.
Author: Lisa Chamberlain James and Barry Drees
Journal: Regulatory Rapporteur
Date: Vol. 17, Issue 9, September 2020
Clinical-Trials-Insight-Cover-Summer-2020
Assistance, Acceleration and Augmentation
AI is set to play a significant role in regulatory and medical writing in the very near future. Dr Barry Drees of Trilogy Writing & Consulting, using his more than...
Author: Barry Drees
Journal: Clinical Trials Insight
Date: Summer 2020
ICT-Magazine-The-Future-Awaits-Us-Article-May-2020
The Future Awaits Us
Off the back of the release of Trilogy Writing & Consulting’s second special edition magazine, EPC sits down with Barry Drees to expand on medical writing trends in the industry....
Author: Barry Drees
Journal: European Pharmaceutical Contractor, EPC
Date: May 2020